Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 3CNS 3Thoracic 2Other hematologic neoplasm 2Head & Neck 2Tumor-Agnostic 1Plasma cell 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Carboplatin 205pembrolizumab 169Pemetrexed 144Cisplatin 126Paclitaxel 78durvalumab 75osimertinib 70Nivolumab 68Docetaxel 66Specimen Handling 64atezolizumab 60Magnetic Resonance Spectroscopy 54Etoposide 47Gemcitabine 46Radiotherapy 45Radiosurgery 40130-nm albumin-bound paclitaxel 36Drug Therapy 33Bevacizumab 29Cetuximab 28Ipilimumab 27cemiplimab 25Taxes 24tislelizumab 21Immunoglobulin G 21Radiation 20Platinum 20Biopsy 20amivantamab 19Disulfides 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
omipalisib × Thoracic × 90 days × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02642042 2026-05-29

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
60 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡